MedBulletinsAura Celeste
Pulmonology

What's next in pulmonology — November 19, 2026

🎧 Listen to this issueAudio newscast · 4:27 min

This issue covers four milestones with verifiable dates between January and May 2027: two applications under FDA review with a target or expected decision date communicated by the companies (inhaled amikacin liposome in MAC lung disease and tozorakimab in COPD), the review of nebulized treprostinil in idiopathic pulmonary fibrosis, and the ATS 2027 congress.

1. Inhaled amikacin liposome from diagnosis in MAC lung disease

[Pending regulatory decision] [United States] [PDUFA target date: January 28, 2027, per Insmed]
What it is: Priority-review sNDA for full approval of ARIKAYCE (Insmed) in Mycobacterium avium complex lung disease as part of a combination antibacterial regimen, based on ENCORE (phase 3b, randomized, double-blind, placebo-controlled; n = 425 randomized at 177 sites; patients with a new occurrence of MAC lung infection who had not received antibiotics, 82.4% with a first infection and 17.6% with a second or third; ARIKAYCE + azithromycin + ethambutol vs placebo + the same regimen, 12 months + 3 off treatment). It met its primary endpoint (change in respiratory symptom score at month 13) and the multiplicity-controlled culture-conversion secondary endpoints, according to the manufacturer's release.
What problem it solves: US approval is currently accelerated and limited to refractory disease in adults with limited or no alternative treatment options; in new patients the standard is an oral macrolide–ethambutol–rifamycin regimen with unsatisfactory conversion and relapse rates.
Critical take: manufacturer-sponsored trial with a symptom-questionnaire primary endpoint rather than mortality or lung function; the release gives no effect sizes. Local implementation depends on availability, cost, support, and capacity for daily nebulization.

Sources

2. Tozorakimab (anti-IL-33) in COPD with exacerbations

[Pending regulatory decision] [United States; also under review in the EU, Japan and China] [Decision expected: first quarter of 2027, per AstraZeneca]
What it is: Priority-review BLA for tozorakimab 300 mg every 4 weeks as add-on maintenance treatment in adults with COPD. OBERON and TITANIA (replicate phase 3, double-blind, placebo-controlled, 52 weeks; n = 2,306 randomized across both trials; ≥2 moderate or ≥1 severe exacerbation in the prior 12 months; former and current smokers, any eosinophil count) met the primary endpoint, the annualized rate of moderate-to-severe exacerbations in former smokers (−29% in OBERON and −34% in TITANIA). In the integrated analysis of OBERON, TITANIA and the PROSPERO extension (up to 104 weeks), in former smokers: moderate/severe exacerbations fell 32% (1.37 vs 2.02 per year; p < 0.0001), but severe exacerbations fell 21% without significance (p = 0.0587).
What problem it solves: patients who keep exacerbating on triple inhaled therapy only have biologics (dupilumab, mepolizumab) if they have an eosinophilic phenotype; for the rest, roflumilast or azithromycin remain.
Critical take: the primary endpoint was defined in former smokers and, in them, the integrated analysis did not significantly reduce severe exacerbations; the 104-week data come from the sponsor. The OBERON and TITANIA results were published in the New England Journal of Medicine; read the full article before changing practice.

Sources

3. Nebulized treprostinil in idiopathic pulmonary fibrosis

[Pending regulatory decision] [United States] [Review completion expected: late April 2027, per United Therapeutics]
What it is: sNDA for Tyvaso (nebulized treprostinil) in IPF, based on TETON-1 (NCT04708782) and TETON-2 (NCT05255991), phase 3, randomized, double-blind, placebo-controlled, 52 weeks, sponsored by United Therapeutics. Combined difference in change in absolute FVC from baseline to week 52: 111.8 mL (Hodges-Lehmann estimate; 95% CI 79.7–144.0; p < 0.0001), with statistical significance in most key secondary endpoints (clinical worsening, acute IPF exacerbation, percent predicted FVC, K-BILD, DLCO).
What problem it solves: current antifibrotics (nintedanib, pirfenidone and, since 2025, nerandomilast) slow but do not stop FVC decline; an inhaled drug with a different mechanism could be added on.
Critical take: industry sponsored, FVC is an intermediate endpoint, and the company has not published an exact PDUFA date; tolerability and cost outside the trial remain to be seen.

Sources

4. ATS 2027 congress

[Congress] [United States] [Confirmed date: May 14, 2027]
What it is: The American Thoracic Society International Conference, May 14–19, 2027, in New Orleans; the usual showcase for late-breaking trials in pulmonary and critical care medicine.
What problem it solves: it concentrates phase 3 presentations (antifibrotics, COPD and asthma biologics, pulmonary hypertension), some published simultaneously.
Critical take: a congress presentation is not a peer-reviewed paper.

Sources

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.